12 October 2021 LungLife AI, Inc. (the “Company” or “LungLife”) PLA Code application submitted in first step in reimbursement process LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces it has submitted its application for a Proprietary Laboratory Analysis (PLA) code to the American Medical […]
9 September 2021 LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer enhanced by artificial intelligence, announces its maiden unaudited half-year report for the six months ended 30 June 2021 following admission to trading on AIM on 8 […]
LungLife AI licensure/accreditation information posted here.